Biotechnology

Travere Therapeutics

Bank of America Analyst Maintains Buy Rating on Travere Therapeutics with $50 Target Price

Travere Therapeutics Completes $525 Million Convertible Note Issuance for Refinancing and Operations

Travere Therapeutics Receives 'Modest Buy' Consensus Rating from Thirteen Analysts

Travere Therapeutics issues convertible notes and repurchases existing convertible notes

Travere Therapeutics Insider Sells Shares, Raises Short-Term Sell Pressure Concerns

Travere Therapeutics Launches $400 Million Underwritten Senior Convertible Notes Offering

Evercore ISI and Citigroup Analysts Maintain Buy Rating on Travere Therapeutics

Travere Therapeutics released FY2026 Q1 earnings on May 4 After-Market EST, actual revenue USD 127.2 M (forecast USD 137.6 M), actual EPS USD -0.4038 (forecast USD -0.3012)

Travere Therapeutics Reports Strong First Quarter Earnings, Filspari Sales Surge

Jennison Associates LLC Significantly Reduced Holdings in Travere Therapeutics

Travere Therapeutics to Release FY2026 Q1 Earnings on May 4 After-Market EST, Forecast Revenue USD 136.82 M, EPS USD -0.3012

Evercore ISI and H.C. Wainwright Analysts Maintain Buy Rating on Travere Therapeutics

Travere Therapeutics CFO Sandra Calvin sold stocks and exercised options

Travere Therapeutics released FY2025 Q4 earnings on February 19 After-Market EST, actual revenue USD 129.69 M (forecast USD 147.68 M), actual EPS USD 0.0302 (forecast USD 0.0054)

Travere Therapeutics released FY2025 annual earnings on February 19 After-Market (EST), actual revenue USD 490.73 M (forecast USD 508.4 M), actual EPS USD -0.2863 (forecast USD -0.3266)

Travere Therapeutics Exceeds Earnings Expectations in Q4 Earnings Report

Travere Therapeutics to Release Quarterly Earnings Report

Travere Therapeutics to Release FY2025 Q4 Earnings on February 19 After-Market EST, Forecast Revenue USD 147.68 M, EPS USD 0.0054

Travere Therapeutics Inc. Receives Consensus Rating of 'Modest Buy', Target Price Increased

Travere Therapeutics Inc. CEO Disposes of Company Common Stock

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

TVTX

Bank of America Securities analyst Jason Zemansky has maintained a Buy rating on Travere Therapeutics (TVTX) with a price target of $50.00. The stock closed at $44.10. The analyst consensus is a Strong Buy with an average price target of $53.42, indicating a 21.13% upside. H.C. Wainwright also reiterated a Buy rating with a $57.00 target.

Tip Ranks

Bank of America

Biogen

Insmed

Ligand Pharmac-B

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Bank of America Securities Remains a Buy on Travere Therapeutics (TVTX)

Travere Therapeutics has completed a US$525 million offering of 0.50% Convertible Senior Notes due 2032 to refinance higher-coupon debt and support its operations. This refinancing aims to enhance the company's balance sheet flexibility, particularly for its FILSPARI product, which is crucial for its growth. Despite the refinancing, challenges remain regarding FILSPARI's market uptake and regulatory risks. Analysts project significant revenue growth by 2029, but investor caution is advised due to ongoing execution risks and market pressures.

Simplywall

Travere’s US$525 Million Convertible Refi Might Change The Case For Investing In Travere Therapeutics (TVTX)

VTVT

RTSL

Vector Science & Therapeutics has entered an option agreement to invest up to $1 million for a 15% equity stake in LyoGenesis Plus, which is acquiring MPP Group LLC, an FDA-registered cGMP manufacturing organization. This agreement allows Vector to secure a long-term manufacturing platform for its peptide formulations without the costs of building a facility. The partnership aims to develop 22 novel pharmaceutical-grade peptide formulations, leveraging MPP's capabilities to meet the growing $80.8 billion peptide market.

PR Newswire

vTv Therap

Rapid Therapeutic Science Laboratories, Inc.

ALPS Medical Breakthrough

SPDR S&P Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News

StockTitan

Nasdaq

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News

Travere Therapeutics has issued $525 million in 0.50% Convertible Senior Notes due 2032, with net proceeds of approximately $508.5 million. The funds will be used to repurchase $221.4 million of existing convertible notes due 2029 and for general corporate purposes. This refinancing extends some debt maturities to 2032 but may dilute future shareholders. Analysts rate TVTX stock as a Buy with a $57.00 price target, while AI analysis suggests a Neutral outlook due to high leverage and inconsistent profitability.

JPMorgan Chase

Jefferies Financial

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Travere Therapeutics Issues New Convertible Notes to Refinance Debt

Elizabeth Reed, an insider at Travere Therapeutics, sold 2,076 shares of the company's stock at an average price of $43.95, totaling $91,240.20. This sale, executed under a Rule 10b5-1 trading plan, reduced her stake by 1.93%. The company recently reported a Q1 EPS of $0.05, beating estimates, and a 55.6% revenue increase year-over-year. Multiple executives have sold shares, raising concerns about short-term selling pressure. Analysts have upgraded price targets following positive earnings, with TD Cowen raising its target to $60 and Wells Fargo to $50.

Market Beat

Elizabeth Reed Sells 2,076 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. has priced its upsized offering of $475 million in convertible senior notes due 2032, increasing from the initial $400 million. The offering is expected to close on May 11, 2026. Proceeds will be used to repurchase $221.4 million of its 2029 convertible notes and for general corporate purposes. The notes will accrue interest at 0.50% per annum and are convertible under certain conditions. Travere may redeem the notes after May 21, 2029, subject to specific stock price conditions.

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes | TVTX Stock News

Travere Therapeutics(TVTX.US)

Bank of America Securities Remains a Buy on Travere Therapeutics (TVTX)

Travere’s US$525 Million Convertible Refi Might Change The Case For Investing In Travere Therapeutics (TVTX)

Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News

Travere Therapeutics Issues New Convertible Notes to Refinance Debt

Elizabeth Reed Sells 2,076 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes | TVTX Stock News